Sugi Predict

Sugi Predict / Compounds / SCHEMBL1732438

SCHEMBL1732438

SCHEMBL1732438

CCCCCNC(=O)[C@H](Cc1cccc(N2CC(=O)N(Cc3ccc(OC)cc3)S2(=O)=O)c1)NC(=O)C(Cc1ccccc1)NC(C)=O

nearest known ligand 0.53

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ PTPN1 P18031 15/20 0.53
▸ KLKB1 P03952 1/20 0.44
▸ PTPRA P18433 4/20 0.43
▸ PTPN2 P17706 1/20 0.43
▸ PLG P00747 2/20 0.43
▸ PRSS1 P07477 2/20 0.43
▸ PRSS2 P07478 2/20 0.43
▸ PRSS3 P35030 2/20 0.43
▸ TSHR P16473 1/20 0.42
▸ TACR2 P21452 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1732436 1.00 PTPN1 (0.53) PTPN1KLKB1PTPRAPTPN2PLG
SCHEMBL1732761 0.94 PTPN1 (0.54) PTPN1KLKB1PTPRAPTPN2PLG
SCHEMBL1732762 0.94 PTPN1 (0.54) PTPN1KLKB1PTPRAPTPN2PLG
SCHEMBL6141529 0.93 PTPN1 (0.49) PTPN1KLKB1PTPRAPTPN2PLG
SCHEMBL6282167 0.90 PTPN1 (0.62) PTPN1KLKB1PLGPRSS1PRSS2
SCHEMBL1732367 0.89 PTPN1 (0.54) PTPN1KLKB1PTPRAPTPN2PLG
SCHEMBL1732320 0.88 PTPN1 (0.47) PTPN1PTPRAPLGPRSS1PRSS2
SCHEMBL1731123 0.88 PTPN1 (0.41) PTPN1PLGPRSS1PRSS2PRSS3
SCHEMBL1731127 0.88 PTPN1 (0.41) PTPN1PLGPRSS1PRSS2PRSS3
SCHEMBL6151250 0.87 PTPN1 (0.44) PTPN1KLKB1PLGPRSS1PRSS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1492780-B1 5-SUBSTITUTED 1,1-DIOXO-¬1,2,5 THIAZOLIDINE-3-ONE DERIVATIVES AS PTPASE 1B INHIBITORS NOVARTIS AG (CH) 2011-11-23 — — EP disclosed
EP-2341049-A1 5-substituted 1,1-dioxo-[1,2,5]thiazolidine-3-one derivatives as PTPASE 1B inhibitors Novartis AG (CH) 2011-07-06 — — EP disclosed
US-20080139576-A1 5-Substituted 1,1-Dioxo- 1,2,5- Thiadiazolidin-3-One Derivatives NOVARTIS AG (CH) 2008-06-12 — — US disclosed
US-7291635-B2 5-substituted 1,1-dioxo-1,2,5,-thiadiazolidin-3-one derivatives NOVARTIS AG (CH) 2007-11-06 — — US disclosed
US-20050090502-A1 Protein tyrosine phosphatase 1B inhibitors alone or incombination with other antidiabetic, antilipemic, anticholesterol or hypotensive agents NOVARTIS AG (CH) 2005-04-28 — — US disclosed
US-20040023974-A1 Cyclic sulfamide derivatives and methods of use COPPOLA GARY MARK 2004-02-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080139576-A1 5-Substituted 1,1-Dioxo- 1,2,5- Thiadiazolidin-3-One Derivatives PTPRS, PTPRJ, IRS1 PTPN1 10/4885KLKB1 2836/4885PTPRA 17/4885
US-20050090502-A1 Protein tyrosine phosphatase 1B inhibitors alone or incombination with other antidiabetic, antilipemic, anticholesterol or hypotensive agents PTPRS, PTPMT1, PTPN1 PTPN1 3/4885KLKB1 3521/4885PTPRA 27/4885
US-20040023974-A1 Cyclic sulfamide derivatives and methods of use PTPRS, PTPA, PTPMT1 PTPN1 9/4885KLKB1 2925/4885PTPRA 19/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.